Perioperative and functional outcomes of salvage versus primary Holmium laser enucleation of the prostate: Evidence-based on controlled studies

Wang, Li; Chen, Xiaobin; Li, Kunpeng; Yin, Shan; Zhu, Ping-yu

doi:10.1016/j.asjsur.2023.05.003

Cited by 1 publication

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27 Although the studies included in this meta-analysis only involved patients with BPH undergoing primary surgery, it is interesting that related studies have shown that salvage HoLEP is still a feasible and effective method for treating residual benign prostatic hyperplasia. 33 In all relevant studies, only one case of transurethral resection syndrome occurred in TURP, and no significant difference was found between the two groups; however, the incidence of hyponatremia in HoLEP was significantly lower. This result may be related to the less invasive nature of HoLEP and the availability of normal saline as a perfusion fluid in HoLEP.…”

Section: Discussionmentioning

confidence: 89%

See 1 more Smart Citation

Comparison of holmium laser enucleation and transurethral resection of prostate in benign prostatic hyperplasia: a systematic review and meta-analysis

Feng¹,

Chen²,

Zou³

et al. 2023

J Int Med Res

View full text Add to dashboard Cite

Transurethral resection of the prostate (TURP) is the gold-standard classical method for the treatment of benign prostatic hyperplasia (BPH). In minimally invasive surgery, holmium laser enucleation of the prostate (HoLEP) is considered an alternative option. In this systematic review and meta-analysis, we aimed to comprehensively evaluate the advantages and disadvantages of TURP and HoLEP the treating BPH. We comprehensively searched PubMed, Cochrane Library, EMBASE, and Web of Science databases for all randomized controlled trials published before 1 December 2022 comparing HoLEP and TURP. The study protocol is registered on INPLASY (DOI: 10.37766/inplasy2023.5.0065). Compared with TURP, HoLEP required longer operation time but shorter catheter duration, hospital stay, and bladder irrigation time, as well as less postoperative irrigation. With HoLEP, maximum urinary flow rate at 12 and 24 months after surgery; post-void residual volume at 1, 6, and 12 months; and International Prostate Symptom Score at 12 months after surgery were superior to those with TURP. HoLEP was associated with significantly lower risk of hyponatremia, blood transfusion, and urethral stricture but greater risk of postoperative dysuria. Compared with TURP, HoLEP had better curative efficacy at 6, 12, and 24 months after operation and lower incidence of adverse events in patients with BPH.

show abstract

Section: Discussionmentioning

confidence: 89%

Section: Discussionmentioning

confidence: 99%